An open-label study was completed in 2016 in the UK to analyze the feasibility, safety and efficacy of psilocybin in treating clients with unipolar treatment-resistant depression with promising success; Even though the research was tiny and included only twelve patients, seven of All those patients fulfilled formal conditions for remission a single